Cancer psychoneuroimmunology is one of the interdisciplinary and expanding fields in cancer sciences that investigates the interaction between the nervous system, psychological processes, the endocrine system, and the immune system, and tries to explain the biological mechanisms related to the mind-body relationship in the formation and progression of cancer. In this framework, cancer is not merely considered as a cellular and molecular process independent of the mental state of the individual, but a set of psychological, neurological, hormonal, and immune factors can affect the patient's biological status along with genetic, environmental, and therapeutic factors. Chronic psychological stress, anxiety, depression, feelings of insecurity, intolerance of uncertainty, and the constant experience of threat from a cancer diagnosis can activate a network of physiological responses, the most important of which is the activation of the pituitary-adrenal axis or the HPA axis. This axis is one of the most important systems for regulating the body's response to stress, and under normal conditions, with the activation of the hypothalamus and the release of hormones. CRH, pituitary stimulation and ACTH secretion, and ultimately the release of cortisol from the adrenal cortex, help the body adapt to short-term threats.
In situations of acute stress, the activation of the HPA axis is usually considered an adaptive mechanism, as the temporary increase in cortisol helps regulate metabolism, mobilize energy, and modulate the inflammatory response. However, when stress departs from a short-term state and becomes a chronic, ongoing experience, the normal regulation of this axis may be disrupted. In cancer patients, stress can begin as soon as the diagnosis is received and continue during various stages of treatment, surgery, chemotherapy, radiation therapy, waiting for test results, worry about recurrence, and fear of the future. The persistence of such conditions can alter the pattern of the release of stress hormones and affect the complex interaction between the nervous system and the immune system. Therefore, the main issue in cancer psychoneuroimmunology is not simply the increase or decrease of a particular hormone, but the disruption of the dynamics and regulation of a network of neurological, hormonal, and immune messages that help maintain physiological balance under normal conditions.
One of the most important pathways in this area is the effect of chronic stress on the function of immune cells involved in the identification and control of abnormal cells. The immune system can identify and remove cells with abnormal changes through a complex set of mechanisms, including natural killer cells or NK, T lymphocytes, dendritic cells, macrophages, and a wide network of cytokines. Chronic stress and persistent changes in neuroendocrine messaging can modulate the function of some of these immune components. In particular, changes in glucocorticoid and catecholamine signals can affect immune cell migration, NK cell activity, T lymphocyte function, and cytokine production. From this perspective, the relationship between psychological stress and cancer should be considered as a network and multifactor, not a linear relationship in which stress alone causes cancer or determines the prognosis of the disease.
One of the key concepts in this context is chronic inflammation. Prolonged stress can alter the regulatory balance of inflammatory networks and set the stage for the activation of pathways that are associated with persistent inflammation. Chronic inflammation is of great importance in cancer biology, as certain inflammatory processes can affect the microscopic environment of the tumor, angiogenesis, tissue regeneration, cell migration, and the interaction of tumor cells with immune cells. The tumor environment is also a dynamic structure in which cancer cells interact with immune cells, fibroblasts, endothelial cells, messenger molecules, and extracellular matrix. In this environment, dysregulation of immunoregulation may create a situation in which a form of tolerance or suppression of the antitumor immune response develops instead of effective removal of abnormal cells.
Understanding this process is of fundamental importance for psychoneuroimmunology, as it shows that the patient's psychological experience can interact with the state of the body through physiological pathways. Of course, this connection does not mean that anxiety or negative thoughts directly cause cancer. Cancer is a complex disease that is influenced by an array of genetic, environmental, behavioral, metabolic, infectious, and cellular factors, and the responsibility for causing the disease cannot be attributed to the patient's mental state. The importance of psychoneuroimmunology lies in studying how psychosocial conditions, especially chronic stress, can affect certain biological processes associated with the disease and tolerance to treatment in a person who has been diagnosed with cancer.
On the other hand, the sympathetic nervous system, along with the HPA axis, also plays an important role in this interaction. Psychological stress increases the activity of the sympathetic system and releases noradrenaline and adrenaline. These chemicals can affect various cellular processes through adrenergic receptors found in many cells and tissues. In the tumor environment, sympathetic messaging can be associated with pathways related to inflammation, angiogenesis, cell migration, and the interaction of tumor cells with the surrounding environment. This suggests that the brain and nervous system are not only recipients of cancer-induced messages, but can also influence the environment of the disease through neural and hormonal pathways.
Another important concept is changes in circadian rhythms. Cancer patients may experience sleep disturbances due to anxiety, pain, medical treatments, hospitalizations, taking certain medications, and ongoing worries. Insufficient sleep and circadian rhythm disorders can affect immune system function and hormonal regulation, and can become a factor in exacerbating fatigue, mood disorders, and reduced adaptive capacity. From this perspective, the relationship between stress, sleep, inflammation, and immune function can create a reinforcing cycle in such a way that sleep anxiety disrupts sleep, sleep disorder reduces stress tolerance, and increased physiological stress can lead to exacerbation of fatigue and psychological distress.
In psychoneuroimmunology, the role of cytokines is also of particular importance. Cytokines are signaling molecules that are involved in regulating immune and inflammatory responses, creating a two-way connection between the brain and the immune system. Changes in inflammatory status can affect neurological function and the experience of symptoms such as fatigue, decreased motivation, sleep disturbances, changes in appetite, and decreased mood. This set of symptoms is of great clinical importance in cancer patients, as they may be partly due to the disease itself, partly due to treatment, and partly due to psychological and inflammatory processes. Therefore, the psychoneuroimmunological approach attempts to investigate their interrelationship rather than completely separating physical and psychological symptoms.
At the applied level, this perspective can shed light on the place of psychological interventions in comprehensive cancer care. Although psychological interventions are not a substitute for anti-cancer therapies and should not be interpreted as such, reducing stress, improving sleep, strengthening coping skills, regulating emotion, increasing social support, and promoting a sense of control can be part of supportive patient care. Interventions such as cognitive behavioral therapy, mindfulness-based interventions, acceptance and commitment-based therapy, relaxation training, stress management interventions, and some meaning-based approaches can be used to reduce psychological distress and improve disease adaptation. The importance of these interventions in the context of psychoneuroimmunology is not because they directly treat the tumor, but because they can modulate some of the psychological and behavioural factors associated with the physiological load of stress.
From a psycho-oncology perspective, Distress assessment can also be part of this approach. Early identification of psychological distress, anxiety, depression, sleep disturbance, pain, fatigue, communication problems, and concern about recurrence allows the treatment team to design supportive interventions tailored to the patient's needs. In such a model, the patient is not seen merely as a carrier of the tumor, but rather as an individual with a psychological, neurological, hormonal, immune, familial, and social network. The same view can pave the way for the development of integrated care models in which the oncologist, psychologist, psycho-oncology, nurse, and other members of the treatment team work together in a coordinated framework.
Despite the importance of this area, the interpretation of psychoneuroimmunological findings should be done with scientific caution. The available evidence supports an association between chronic stress, HPA-driven activity, the sympathetic nervous system, inflammation, and some immune markers, but these relationships are complex and cannot be concluded that any type of psychological stress causes cancer progression or that stress reduction alone can stop tumor growth. Many studies also face differences in the type of cancer, the stage of the disease, the type of treatment, the characteristics of the sample, the biomarkers to be measured, and the method of assessing stress. Therefore, the direct transfer of laboratory findings or observed correlations to clinical decision-making should be done according to the quality of the evidence and methodological limitations.
Another important challenge is to differentiate the effect of stress from other concurrent factors. Cancer patients may experience psychological stress, pain, inflammation, sleep deprivation, dietary changes, medication use, reduced physical activity, and complications of treatment. All of these factors can affect the nervous, endocrine and immune systems. Therefore, future research should move towards longitudinal designs, repeated biological and psychological measurements, and the use of multilevel models to be able to more accurately determine the temporal trajectory and direction of relationships between variables. The simultaneous use of markers such as cortisol, inflammatory markers, NK cell activity, emotion regulation markers, distress, sleep quality, and variables related to the tumor environment can provide a more complete picture of this interaction.
In the future, the combination of psychoneuroimmunology with wearable technologies, digital medicine, and longitudinal data analysis can also allow for dynamic monitoring of stress and physiological status of patients. Measurement of sleep patterns, heart rate, heart rate variability, physical activity, and some physiological indicators can help identify periods of increased stress along with psychological assessments. Of course, such technologies should be used as a complementary tool, not a substitute for specialized clinical evaluation, and issues such as privacy, data security, interpretability, and measurement error should also be considered.
Cancer psychoneuroimmunology provides a multidimensional picture of the interaction of the mind, brain, hormones, immune system, and tumor environment. Chronic psychological stress can interact with cancer-related biological processes through changes in the HPA axis, sympathetic nervous system activity, hormonal secretion patterns, inflammation, sleep, and the regulation of immune responses; however, this association is multifactorial and uncertain, and should not be reduced to a simple "stress equal to cancer progression" relationship. Value The main focus of this approach in psycho-oncology is that it highlights the necessity of simultaneous care of the body and mind and shows that the management of psychological distress, anxiety, sleep disorders, and adjustment problems is an integral part of comprehensive care for patients with cancer. The move from purely tumor-centered treatment to integrated, person-centered, and biopsychosocial care can pave the way for more rigorous research and more targeted interventions, interventions in which reducing psychological suffering, improving quality of life, and supporting the patient's coping capacity, along with medical treatment of cancer, are considered as complementary components of specialized care.